A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Retained Gastric Contents Using Gastric Ultrasound in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus
Latest Information Update: 29 Dec 2025
At a glance
- Drugs Tirzepatide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Eli Lilly and Company
Most Recent Events
- 29 Dec 2025 New trial record